Activated Protein C Resistance in Type I Diabetes
- Gabriella Gruden, MD,
- Carla Olivetti, MD,
- Paolo Cavallo-Perin, MD,
- Mario Bazzan, MD,
- Stefania Stella, MD,
- Giacomo Tamponi, MD and
- Gianfranco Pagano, MD
- Department of Internal Medicine, University of Turin Turin, Italy
- Department of Experimental Medicine and Oncology, Division of Haematology, University of Turin Turin, Italy
- Address correspondence to P. Cavallo-Perin, MD, Department of Internal Medicine, C.so A.M.Dogliotti 14, 1-10126 Turin, Italy.
Abstract
OBJECTIVE To compare activated protein C (aPC) sensitivity in 37 type I diabetic patients and 33 healthy control subjects.
RESEARCH DESIGN AND METHODS In this study, 37 type I diabetic patients and 33 healthy control subjects without personal or familial history of venous thrombosis and coagulation disorders, infections, intercurrent conditions, serum lupus anticoagulant, clinical cardiovascular complications, or drugs were examined.
RESULTS The aPC ratio (aPTT [activated partial thromboplastin time] with and without aPC) was significantly lower in the type I diabetic patients than in the control subjects (P = 0.005).
CONCLUSIONS These results suggest that the final steps of the protein C/S inhibiting system could be abnormal in type I diabetes.
- Received April 12, 1996.
- Revision received September 12, 1996.
- Accepted September 12, 1996.
- Copyright © 1997 by the American Diabetes Association
